Pep-Seq: A Novel Technology for Discovering Antimicrobial Peptides ID: 2016-014

Pep-Seq is an innovative technology designed to accelerate the discovery of new antimicrobial peptides using genetically encoded libraries and deep sequencing.

Technology Overview

This technology leverages a combination of genetically encoded peptide libraries and deep sequencing to identify peptides with antimicrobial activities. By engineering a library of 200,000 colonies, each expressing a unique peptide variant, Pep-Seq enables the efficient screening of peptides for antimicrobial properties. The approach focuses on understanding the correlation between peptide structure, such as hydrophobicity and cysteine content, and antimicrobial activity, aiming to optimize peptide scaffolds using advanced cyclopeptide and lasso peptide technologies for enhanced stability and effectiveness.

Key Advantages

• High-throughput screening of peptides for antimicrobial activity
• Identification of peptides with enhanced stability and drug-like properties through cyclopeptide and lasso peptide technologies
• Ability to target specific biological pathways with refined peptide inhibitors
• Addresses the critical health challenge of antibiotic resistance with innovative discovery methods

Problems Addressed

• Lack of new antibiotics to combat rising antibiotic resistance
• Inefficiency of traditional antibiotic discovery platforms
• Need for more stable, effective antimicrobial peptides with drug-like properties

Market Applications

• Development of new antimicrobial agents for pharmaceutical companies
• Antibiotic resistance research and development
• Biotechnological research tools for studying peptide structure and function
• Enhanced methods for rapid screening of peptide-based therapeutics

Additional Information

Technology ID: 2022-002
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025